Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
497
-
Total 13F shares, excl. options
-
122M
-
Shares change
-
-2.06M
-
Total reported value, excl. options
-
$5.85B
-
Value change
-
-$142M
-
Put/Call ratio
-
0.39
-
Number of buys
-
236
-
Number of sells
-
-257
-
Price
-
$47.81
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2024
597 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q4 2024.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 497 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122M shares
of 124M outstanding shares and own 99% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (17.6M shares), VANGUARD GROUP INC (13.3M shares), STATE STREET CORP (7.18M shares), SNYDER CAPITAL MANAGEMENT L P (4.17M shares), BANK OF AMERICA CORP /DE/ (3.45M shares), ALLIANCEBERNSTEIN L.P. (3.07M shares), GEODE CAPITAL MANAGEMENT, LLC (3.06M shares), MACQUARIE GROUP LTD (2.91M shares), JPMORGAN CHASE & CO (2.39M shares), and Invesco Ltd. (2.37M shares).
This table shows the top 497 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.